The affinity and selectivity of α-adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.


Journal

Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369

Informations de publication

Date de publication:
04 2022
Historique:
revised: 19 01 2022
received: 26 11 2021
accepted: 20 01 2022
entrez: 28 2 2022
pubmed: 1 3 2022
medline: 21 4 2022
Statut: ppublish

Résumé

α2-Adrenoceptors, subdivided into α2A, α2B, and α2C subtypes and expressed in heart, blood vessels, kidney, platelets and brain, are important for blood pressure, sedation, analgesia, and platelet aggregation. Brain α2C-adrenoceptor blockade has also been suggested to be beneficial for antipsychotic action. However, comparing α2-adrenoceptor subtype affinity is difficult due to significant species and methodology differences in published studies. Here,

Identifiants

pubmed: 35224877
doi: 10.1002/prp2.936
pmc: PMC8882856
doi:

Substances chimiques

Antidepressive Agents 0
Antipsychotic Agents 0
Receptors, Adrenergic, alpha-1 0
Yohimbine 2Y49VWD90Q

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00936

Informations de copyright

© 2022 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

Références

Eur J Pharmacol. 2003 Feb 21;462(1-3):33-40
pubmed: 12591093
Br J Pharmacol. 1990 Apr;99(4):803-9
pubmed: 1972896
Br J Pharmacol. 1985 Jun;85(2):349-59
pubmed: 2862942
Biochim Biophys Acta. 1995 Apr 28;1266(2):207-14
pubmed: 7742388
J Pharmacol Exp Ther. 2012 Mar;340(3):750-64
pubmed: 22178752
Pharmacol Ther. 2001 Sep;91(3):215-43
pubmed: 11744068
Pharmacol Toxicol. 1995 Jun;76(6):353-64
pubmed: 7479575
J Pharmacol Exp Ther. 1994 Sep;270(3):946-57
pubmed: 7932207
Eur J Pharmacol. 2020 Dec 15;889:173632
pubmed: 33038419
Br J Pharmacol. 2010 Jul;160(5):1048-61
pubmed: 20590599
Mol Pharmacol. 1989 Mar;35(3):324-30
pubmed: 2564631
Br J Clin Pharmacol. 1990 Dec;30(6):884-8
pubmed: 1981137
Pharmacol Res. 2001 Sep;44(3):195-208
pubmed: 11529686
Mol Pharmacol. 1992 Jul;42(1):1-5
pubmed: 1353247
J Urol. 2002 Jul;168(1):160-3
pubmed: 12050513
Eur J Neurosci. 2000 Mar;12(3):1079-95
pubmed: 10762339
Eur J Pharmacol. 1989 Sep 22;168(3):381-6
pubmed: 2573535
Naunyn Schmiedebergs Arch Pharmacol. 1997 Nov;356(5):570-82
pubmed: 9402036
Neuroscience. 2002;109(4):819-26
pubmed: 11927164
Psychopharmacology (Berl). 2014 Mar;231(5):801-12
pubmed: 24488407
J Pharmacol Exp Ther. 2020 Oct;375(1):1-9
pubmed: 32665319
Anesthesiology. 1992 Nov;77(5):983-91
pubmed: 1359811
Eur J Pharmacol. 1998 Feb 5;343(1):93-101
pubmed: 9551719
Br J Pharmacol. 2011 Nov;164(5):1558-72
pubmed: 21649638
Br J Pharmacol. 2007 Feb;150(4):391-402
pubmed: 17220913
Am J Physiol Regul Integr Comp Physiol. 2002 Aug;283(2):R287-95
pubmed: 12121839
Cochrane Database Syst Rev. 2015 Aug 26;(8):CD007449
pubmed: 26306578
J Pharmacol Exp Ther. 1986 Jan;236(1):90-6
pubmed: 2867217
World J Urol. 2001 Aug;19(4):251-5
pubmed: 11550783
J Pharmacol Exp Ther. 1995 Jun;273(3):1287-94
pubmed: 7791100
J Pharmacol Exp Ther. 2002 Nov;303(2):805-14
pubmed: 12388667
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804
pubmed: 12388666
J Pharmacol Exp Ther. 1988 May;245(2):600-7
pubmed: 2835476
J Endourol. 2017 May;31(5):427-437
pubmed: 28306333
Br J Pharmacol. 2005 Feb;144(3):317-22
pubmed: 15655528
J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65
pubmed: 7996470
Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12
pubmed: 14610637
J Pharmacol Exp Ther. 1986 Jan;236(1):1-7
pubmed: 2867209
Eur J Pharmacol. 1999 Dec 3;385(2-3):247-53
pubmed: 10607883
CNS Drug Rev. 2002 Summer;8(2):177-92
pubmed: 12177687
J Pharmacol Exp Ther. 2000 Apr;293(1):1-7
pubmed: 10734146
J Mol Med (Berl). 2010 Mar;88(3):289-96
pubmed: 19894027
J Pharmacol Exp Ther. 1993 Mar;264(3):1187-97
pubmed: 8095548
Pharmacol Res Perspect. 2020 Aug;8(4):e00602
pubmed: 32608144
Cardiovasc Ther. 2020 Apr 29;2020:2478781
pubmed: 32426035
Front Psychiatry. 2017 Aug 14;8:144
pubmed: 28855875
Pharmacol Res Perspect. 2022 Apr;10(2):e00936
pubmed: 35224877
Neurochem Int. 2007 Oct;51(5):277-81
pubmed: 17664025
Eur J Pharmacol. 1995 Sep 25;284(3):271-9
pubmed: 8666009
Br J Pharmacol Chemother. 1957 Dec;12(4):489-97
pubmed: 13489180
Trends Pharmacol Sci. 2015 Apr;36(4):196-202
pubmed: 25771972

Auteurs

Richard G W Proudman (RGW)

Cell Signalling Research Group, Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, C Floor Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK.

Juliana Akinaga (J)

Cell Signalling Research Group, Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, C Floor Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK.

Jillian G Baker (JG)

Cell Signalling Research Group, Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, C Floor Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH